APOE and pulmonary arterial hypertension: PAH patients have decreased levels of apolipoprotein E (ApoE), a factor that reduces circulating low-density lipoprotein (LDL), and consequently, atherogenesis, and decreased levels of PPARg in the lungs, and this was associated with decreased levels of adiponectin, leading to IR.